Abstract 20P
Background
In China, new breast cancer (BC) patients (pts) in county regions (including rural areas) account for more than 40% of all BC cases each year. No studies have reported the disease characteristics and treatment patterns of BC pts in China counties. This study aimed to explore the treatment patterns of BC pts in county-level hospitals in China.
Methods
CHASE001 was an observational, multicenter study assessing real-world treatment patterns among pts with HER2+ or HR+/HER2- BC conducted at 26 sites in county areas of China, including four cohorts (HER2+ early BC (eBC), HR+/HER2- eBC, HER2+ advanced BC (aBC), and HR+/HER2- aBC). The primary endpoint was treatment patterns within each cohort. The interim results for HER2+ eBC and HR+/HER2- eBC are described here.
Results
628 pts were included (302 in HER2+ eBC and 326 in HR+/HER2- eBC cohort): for HER2+ and HR+/HER2- cohort respectively, median age, 53/51 years; clinical T2, 41.39%/37.73%; clinical N0, 41.72%/45.40%. Of 584 pts who underwent breast cancer surgery, only 10.53% (30/285) received breast-conserving surgery (BCS) in HER2+ and 12.71% (38/299) in HR+/HER2- cohort. Notably, the proportions of adjuvant radiotherapy (RT) following BCS were 46.67% (14/30) in HER2+ and 47.37% (18/38) in HR+/HER2- cohort. In HER2+ cohort, 20.20% (61/302) received neoadjuvant therapy (NAT) while 94.70% (286/302) received adjuvant therapy. 81.97% (50/61) of NAT were HER2 targeted regimens, of which 84.00% (42/50) received dual anti-HER2 target therapy (trastuzumab/pertuzumab). 80.77% (231/286) of adjuvant therapies were HER2 targeted regimens, of which 53.68% (124/231) were dual-targeted. Of pts with positive lymph nodes who received HER2 targeted adjuvant therapy, 75.90% applied dual anti-HER2 target therapy. In HR+/HER2- cohort, 13.50% (44/326) received NAT while 92.02% (300/326) received adjuvant therapy. The most common neoadjuvant and adjuvant chemotherapy regimens were both AC-T (41.67% and 51.79%, respectively).
Conclusions
This analysis showed unsatisfactory adherence to guidelines for BCS, RT, and NAT, but higher adherence for adjuvant anti-HER2 therapy. Further action was needed to ensure that patients in Chinese county had access to high quality and guideline centric care.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract